Climb Bio

What Climb Bio does

Climb Bio operates a pre-commercial business model with no approved products and no current revenue, relying on capital markets to fund clinical development. Revenue is expected to be generated through sales of approved drug candidates post-regulatory approval, with planned distribution via specialty pharmacies and infusion centers for biotech therapies. The company has established a strategic partnership with Beijing Mabworks Biotech for CLYM116 development in Greater China, while retaining global rights outside that region. Leadership includes CEO Aoife Brennan (formerly Biogen, Synlogic), Chairman Douglas Williams (formerly Biogen EVP R&D, Seattle Genetics CSO), and CFO Susan Altschuller (formerly CFO of Cerevel Therapeutics and ImmunoGen), with a board featuring industry veterans from Sarepta, Roche, and Atlas Venture.

Name

Climb Bio

Legal name

Climb Bio, Inc.

Website

https://climbbio.com

Company type

Public

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Short description

Climb Bio is a clinical-stage biotechnology company developing proprietary monoclonal antibodies—budoprutug (anti-CD19) and CLYM116 (anti-APRIL)—for B-cell-mediated autoimmune diseases including primary membranous nephropathy, immune thrombocytopenia, systemic lupus erythematosus, and IgA nephropathy.

Ownership category

akta.pro rank

Product category

Immunology Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Monoclonal Antibody Therapeutics (mAbs) (HLAAAAAA)

akta.pro secondary industry

Transplant & Immunosuppression Specialty Pharmaceuticals (HLAIACAJ)

Keywords

• Monoclonal antibody therapy
• Autoimmune disease therapeutics
• B-cell depletion therapy
• Clinical-stage biopharmaceuticals
• Immune-mediated disease treatment

Headquarters

HQ city

Redmond

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Pharmaceutical/Biotech Revenue: Pre-commercial clinical-stage biotechnology company with no approved products. Revenue will be generated through sales of approved drug candidates once regulatory approvals are obtained. Pipeline includes budoprutug (anti-CD19 mAb) for autoimmune diseases and CLYM116 (anti-APRIL mAb) for IgA nephropathy.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Core offering

Climb Bio is a clinical-stage biotechnology company developing differentiated monoclonal antibody (mAb) therapeutics for B-cell-mediated immune-mediated diseases. Its pipeline consists of budoprutug, an anti-CD19 mAb for primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus, and CLYM116, an anti-APRIL mAb for IgA nephropathy. Both candidates are investigational therapies currently in Phase 1/2 clinical development with no approved products or commercial revenue.

Product overview

Climb Bio is a clinical-stage biotechnology company developing differentiated monoclonal antibodies (mAbs) for immune-mediated diseases. The company's portfolio consists of two clinical-stage programs: Budoprutug (anti-CD19 mAb) targeting B-cell depletion for autoimmune conditions including primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus; and CLYM116 (anti-APRIL mAb) targeting plasma cells and IgA production for IgA nephropathy. Both candidates are administered intravenously, with budoprutug also in development as a subcutaneous formulation. The company leverages validated B cell targets and proven monoclonal antibody approaches to address areas of high unmet medical need.

Differentiator

Problem solved

Functional benefit

Products and services

• Budoprutug An anti-CD19 monoclonal antibody designed for potent and durable B-cell depletion, with potential for both intravenous (IV) and subcutaneous (SC) administration. Being developed for B-cell-mediated autoimmune diseases including primary membranous nephropathy (Phase 2 PrisMN trial NCT07096843), immune thrombocytopenia (Phase 1b/2a trial NCT07043946), and systemic lupus erythematosus (Phase 1b trial NCT07011043), plus a Phase 1 SC formulation study (NCT07090655).
• CLYM116 A novel anti-APRIL (A PRoliferation Inducing Ligand) monoclonal antibody featuring a unique 'sweeper' mechanism with pH-dependent binding to promote APRIL blockade and degradation, plus Fc-engineering for extended half-life. Being developed for IgA nephropathy, with a Phase 1 trial in healthy volunteers (NCT07248865) and global rights outside Greater China held by Climb Bio under license from Beijing Mabworks Biotech.

Quantifiable outcome

• 60% complete remission, 100% overall remission in Phase 1b trial for primary membranous nephropathy
• +3 more outcomes

Segments4 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

One partnership is on record.

• Beijing Mabworks BiotechcoreStrategic or Co-development Partner · 11 April 2024Beijing Mabworks Biotech is a strategic partner for CLYM116 (anti-APRIL monoclonal antibody). Climb Bio maintains global rights to CLYM116 outside of Greater China, while Mabworks is conducting a parallel Phase 1 study in China and expects to initiate Phase 2 dosing in IgAN patients in Q3 2026. This partnership enables the companies to advance the CLYM116 program simultaneously in different geographic regions.

Scale indicators12 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Argenx: Commercial-stage autoimmune biotech with VYVGART (efgartigimod), an FcRn-targeting antibody approved in ITP and other autoimmune indications. Directly comparable as a B-cell-pathway mAb company with a recently approved ITP asset targeting the same indication as Climb Bio's budoprutug.
• Immunovant: Clinical-stage autoimmune biotech developing anti-FcRn monoclonal antibodies (batoclimab/imdevimbab) across multiple autoimmune indications. Comparable in clinical-stage strategy, autoimmune disease focus, and mAb modality.
• Zenas BioPharma: Clinical-stage biotech advancing obexelimab, a CD19 x CD20 bispecific antibody, in autoimmune indications including IgG4-related disease and ITP. Closest direct CD19-pathway competitor to budoprutug.
• Vera Therapeutics: Late-stage clinical biotech developing atacicept (anti-BAFF/APRIL) for IgA nephropathy. Highly comparable given shared indication with Climb Bio's CLYM116 and overlapping APRIL pathway biology.
• Travere Therapeutics: Commercial-stage rare disease company with Filspari (sparsentan) approved for IgA nephropathy. Comparable as a kidney-focused biotech targeting the same IgAN indication as CLYM116.
• Aurinia Pharmaceuticals: Commercial-stage biotech with voclosporin (Lupkynis) approved for lupus nephritis. Comparable as an autoimmune nephrology-focused company addressing a related kidney indication to Climb Bio's pipeline.

Emerging players

• Cabaletta Bio: Clinical-stage cell therapy biotech developing CD19-directed CAR-T approaches for autoimmune diseases. Comparable target (CD19) and autoimmune indications, though using cell therapy rather than mAb modality.
• Kyverna Therapeutics: Clinical-stage biotech developing CD19-directed CAR-T therapies for autoimmune diseases. Shares CD19 target and autoimmune disease focus with Climb Bio, although pursuing cell therapy rather than mAb modality.

Broad incumbents

• Bristol Myers Squibb: Large pharmaceutical company with approved lupus therapy Saphnelo (anifrolumab) and extensive immunology franchise including deucravacitinib. Competes commercially in SLE and adjacent autoimmune indications pursued by Climb Bio.
• AstraZeneca (Alexion): Rare disease franchise within AstraZeneca with Soliris/Ultomiris (C5 inhibitors) and an expanding autoimmune mAb portfolio. Comparable as a large player in rare autoimmune disease biologics overlapping Climb Bio's patient populations.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/climbbio
• LinkedInlinkedin.com/company/climbbio
• Facebookfacebook.com/ClimbBio

Revenue estimate

Valuation estimate

Number of profiles

Profiles21 records

Funding overview

Funding rounds7 records

Investors21 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Climb Bio